Lactobacillus acidophilus
CAS 68333-16-4
Lactobacillus acidophilus (CAS 68333-16-4) is a pharmaceutical compound with 0 bioactivity targets and 1,256 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Lactobacillus acidophilus is linked to DTXSID301010938 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Lactobacillus Acidophilus | 6205 | SU | MTHSPL |
| LACTOBACILLUS ACIDOPHILUS | 6205 | SU | MTHSPL |
| Lactobacillus acidophilus | 6205 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Lactobacillus acidophilus used for in pharmaceutical contexts?
Lactobacillus acidophilus (CAS 68333-16-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Lactobacillus acidophilus?
Lactobacillus acidophilus has 1,256 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Accidental exposure to product. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Lactobacillus acidophilus also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for S-COCONUT ANTIMICROBIAL PEPTIDE 1 with EU status "permitted".
What clinical phase is Lactobacillus acidophilus in?
No phase 1-4 clinical development badge is rendered for Lactobacillus acidophilus because the matched compound identifier rows do not contain a max-phase value.